Abstract: Background: A growing body of research suggests that oxidative stress and neuroinflammation are early pathogenic features of neurodegenerative disorders.
In recent years, the vitagene system has emerged as a potential target, as it has been shown to have a high neuroprotective power. Therefore, the discovery of molecules capable of activating this system may represent a new therapeutic target to limit the deleterious consequences induced by oxidative stress and neuroinflammation, such as neurodegeneration. Lipoxins are derived from arachidonic acid, and their role in the resolution of systemic inflammation is well established; however, they have become increasingly involved in the regulation of neuroinflammatory and neurodegenerative processes.
Our study aimed at activating the NF-E2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) redox system and increasing lipoxin A4 for the modulation of antioxidant stress and neuroinflammation through the action of two fungi in a rotenone-induced Parkinson’s model. Methods: During the experiment, mice received Hericium erinaceus, Coriolus versicolor or a combination of the two (200 mg/kg, orally) concomitantly with rotenone (5 mg/kg, orally) for 28 days.
Results: The results obtained highlighted the ability of these two fungi and, in particular, their ability through their association to act on neuroinflammation through the nuclear factor-kB pathway and on oxidative stress through the Nrf2 pathway. This prevented dopaminergic neurons from undergoing apoptosis and prevented the alteration of typical Parkinson’s disease (PD) markers and α-synuclein accumulation.
The action of Hericium erinaceus and Coriolus versicolor was also able to limit the motor and non-motor alterations characteristic of PD. Conclusions: Since these two mushrooms are subject to fewer regulations than traditional drugs, they could represent a promising nutraceutical choice for preventing PD.
The studies referred to with Coriolus versicolor and with Hericium erinaceus are based on studies using biomass mushrooms supplied by Mycology Research Laboratories Ltd.
Clinical Articles
The following section outlines the clinical papers, posters and proposals that refer to the clinical use of MRL mushroom nutrition products. This information is for healthcare practitioners only and should not be provided to members of the general public.
Download PDF
Clinical articles
-
Impact of Gastrointestinal Tract on Mushroom Biomass: Deciphering Their Potential on Gut Microbiota Modulation.
Helena Araújo-Rodrigues, Ana Sofia Salsinha, João Bettencourt Relvas, Freni K. Tavaria, Manuela E. Pintado Presented at the the 10th International Human Microbiome Consortium (IHMC) Congress held on June 22-25, 2024 in Rome Italy. -
Redox Modulation of Meniere Disease by Coriolus Versicolor Treatment, a Nutritional Mushroom Approach with Neuroprotective Potential.
Rosanna Di Paola, Rosalba Siracusa, Roberta Fusco, Marialaura Ontario, Gaetano Cammilleri, Licia Pantano, Maria Scuto, Mario Tomasello, Sestina Spanò, Angela Trovato Salinaro, Ali S. Abdelhameed, Vincenzo Ferrantelli, Antonio Arcidiacono, Tilman Fritsch, Gabriella Lupo, Anna Signorile, Luigi Maiolino, Salvatore Cuzzocrea, and Vittorio Calabrese.
Curr Neuropharmacol 2023 Dec 8. PMID: 38073105
-
Mushrooms as Functional Foods for Ménière’s Disease.
Victoria Bell and Tito Horácio Fernandes.
Appl. Sci. 2023, 13, 12348. -
Antioxidants, Hormetic Nutrition, and Autism.
Modafferi Sergio, Lupo Gabriella, Tomasello Mario, Rampulla Francesco, Ontario Marialaura,
Scuto Maria, Trovato Salinaro Angela, Arcidiacono Antonio, Anfuso Carmelina Daniela,
Legmouz Maria, Azzaoui Fatima-Zahra, Palmeri Agostino, Spano’ Sestina, Biamonte Francesca,
Cammilleri Gaetano, Fritsch Tilman, Sidenkova Alena, Calabrese Edward, Wenzel Uwe and Calabrese Vittorio. Curr Neuropharmacol. 2023 Aug 17.